Applied Therapeutics Ownership | Who Owns Applied Therapeutics?
Applied Therapeutics Ownership Summary
Applied Therapeutics is owned by 757.19% institutional investors, 5.70% insiders. Vestal point capital, lp is the largest institutional shareholder, holding 79.67% of APLT shares. Simplify Propel Opportunities ETF is the top mutual fund, with 3.15% of its assets in Applied Therapeutics shares.
APLT Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Applied Therapeutics | 757.19% | 5.70% | -662.89% |
Sector | Healthcare Stocks | 57.43% | 9.41% | 33.16% |
Industry | Biotech Stocks | 69.02% | 8.92% | 22.06% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Vestal point capital, lp | 11.50M | 79.67% | $9.85M |
Vr adviser | 9.99M | 69.21% | $8.55M |
Propel bio management | 9.62M | 66.61% | $8.23M |
Blackrock funding, inc. /de | 9.30M | 64.40% | $7.96M |
Schonfeld strategic advisors | 8.76M | 60.70% | $7.50M |
Vanguard group | 5.55M | 38.44% | $4.75M |
T. rowe price investment management | 5.42M | 37.56% | $4.64M |
Deutsche bank ag\ | 4.47M | 30.95% | $3.84M |
Simplify asset management | 2.82M | 19.52% | $2.41M |
Alyeska investment group | 2.71M | 18.76% | $2.32M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Knoll capital management | 5.57M | 17.54% | $26.03M |
Propel bio management | 9.62M | 8.18% | $8.23M |
Stempoint capital lp | 2.21M | 3.03% | $10.33M |
Vr adviser | 9.99M | 0.59% | $8.55M |
Vestal point capital, lp | 11.50M | 0.58% | $9.85M |
Windsor advisory group | 416.76K | 0.41% | $356.83K |
Tang capital management | 2.43M | 0.14% | $2.08M |
Artal group | 1.01M | 0.12% | $4.71M |
Simplify asset management | 2.82M | 0.12% | $2.41M |
Rock springs capital management lp | 1.92M | 0.06% | $1.64M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Vestal point capital, lp | 11.50M | 0.58% | 10.36M |
Schonfeld strategic advisors | 8.76M | 0.04% | 8.42M |
Blackrock | 6.57M | 0.00% | 5.58M |
T. rowe price investment management | 5.42M | 0.00% | 5.21M |
Propel bio management | 9.62M | 8.18% | 3.05M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Janus henderson group | 35.79K | - | -10.51M |
Perceptive advisors | 860.00K | 0.02% | -7.14M |
Franklin resources | 2.00M | 0.00% | -4.80M |
Frazier life sciences management | - | - | -2.29M |
Adage capital partners gp | 1.96M | 0.00% | -2.15M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Jefferies financial group | 276.70K | 0.00% | 276.70K | $236.91K |
Norges bank | 243.20K | - | 243.20K | $208.23K |
Hrt financial lp | 242.88K | 0.00% | 242.88K | $207.00K |
Aristides capital | 156.51K | 0.03% | 156.51K | $134.00K |
Swiss national bank | 146.90K | 0.00% | 146.90K | $125.78K |
Sold Out
Holder | Change |
---|---|
National bank of canada /fi/ | -4.00 |
True wealth design | -72.00 |
Lindbrook capital | -103.00 |
Newedge advisors | -199.00 |
Accent capital management | -602.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 127 | -11.19% | 109,297,179 | -3.04% | 757 | 0.12% | 79 | -8.14% | 26 | -18.75% |
Sep 30, 2024 | 143 | 41.58% | 112,721,880 | 9.20% | 780 | 11.51% | 85 | 37.10% | 33 | 37.50% |
Jun 30, 2024 | 101 | 1.00% | 103,226,978 | 9.86% | 82 | 1.47% | 62 | -7.46% | 24 | 50.00% |
Mar 31, 2024 | 100 | 12.36% | 93,965,703 | 53.04% | 74 | 1.41% | 67 | 15.52% | 16 | 45.45% |
Dec 31, 2023 | 89 | 56.14% | 61,400,847 | 42.94% | 72 | 3.25% | 58 | 70.59% | 11 | 57.14% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Simplify Propel Opportunities ETF | 3.67M | 3.15% | 850.00K |
T. Rowe Price Small-Cap Value | 3.38M | 2.91% | 3.00M |
Vanguard Total Stock Mkt Idx Inv | 3.10M | 2.67% | - |
iShares Russell 2000 ETF | 2.51M | 2.16% | -49.08K |
T. Rowe Price U.S. SC Value Eq Tr-Z | 1.88M | 1.62% | 1.81M |
SPDR® S&P Biotech ETF | 1.74M | 1.49% | 24.74K |
Janus Henderson Global Life Sciences D | 1.62M | 1.39% | 1.30M |
Janus Henderson Glb Life Scn I2 USD | 1.29M | 1.11% | 1.29M |
Franklin Biotechnology Discv A(acc)USD | 1.26M | 1.09% | - |
Vanguard Institutional Extnd Mkt Idx Tr | 1.26M | 1.08% | - |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Mar 04, 2025 | Perfetti Riccardo | Chief Medical Officer | Sell | $4.56K |
Mar 04, 2025 | Funtleyder Leslie D. | See Remarks | Sell | $6.38K |
Mar 04, 2025 | Chinoporos Constantine | See Remarks | Sell | $196.68 |
Feb 06, 2025 | Funtleyder Leslie D. | See Remarks | Sell | $14.00K |
Feb 06, 2025 | Perfetti Riccardo | Chief Medical Officer | Sell | $52.51K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 6 |
2024 Q4 | - | - |
2024 Q3 | - | 5 |
2024 Q2 | - | 5 |
2024 Q1 | - | 4 |
APLT Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools